Acute renal failure: a rare side effect of sunitinib therapy.
Sunitinib is an oral multiple tyrosine kinase receptor inhibitor. It is usually well tolerated but can cause fatigue, malaise, and rash. Sunitinib-induced cardiotoxicity has been well described, but nephrotoxicity is very rare. Here, we report a rare case of acute renal failure caused by sunitinib therapy in a 73-year-old Caucasian female who was enrolled in a phase II trial of sunitinib therapy for clear cell ovarian cancer. At presentation, her blood urea nitrogen (BUN) was 91 mg/dl and creatinine was 9.2 mg/dl. Sunitinib therapy was discontinued, and she was treated conservatively with intravenous fluid. Creatinine gradually returned to normal, and fatigue resolved. She was diagnosed with sunitinib-induced acute renal failure. The nephrologists and oncologists should be aware of sunitinib-induced rare nephrotoxicity, and patients should be closely monitored.
Department of Internal Medicine, Fairview Hospital, 18101 Lorain Road, Cleveland, OH 44111, USA. kawsarh@ccf.org
Hameem I
HI
Kawsar
Saurabh
S
Bansal
Jonathan L
JL
Myles
D058186:Acute Kidney Injury / Q000139:chemically induced*; D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy*; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib